NASDAQ:HRTX
Heron Therapeutics Stock News
$2.87
+0.0300 (+1.06%)
At Close: May 07, 2024
Heron Therapeutics: Zynrelef (Finally) Approved But With A Narrow Label
02:14am, Friday, 21'st May 2021
Heron Therapeutics: Zynrelef (Finally) Approved But With A Narrow Label
Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important
11:01am, Thursday, 13'th May 2021
Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego, California-based Heron, a commercial-
Heron Therapeutics (HRTX): Over 15% Increase Pre-Market Explanation
08:27am, Thursday, 13'th May 2021
The stock price of Heron Therapeutics Inc (NASDAQ: HRTX) increased by over 15% pre-market. This is why it happened.
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
08:00am, Thursday, 13'th May 2021
SAN DIEGO, May 13, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm
Why Heron Therapeutics Stock Jumped Today
03:33pm, Monday, 10'th May 2021
Investors liked the company's Q1 update.
Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates
10:31am, Monday, 10'th May 2021
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates
08:30am, Monday, 10'th May 2021
SAN DIEGO, May 10, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatm
Want to Make Money in Biotech? Do This First
06:17am, Friday, 07'th May 2021
Keeping track of upcoming events is important.
Will Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should Know
01:49pm, Wednesday, 28'th Apr 2021
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Heron Therapeutics (HRTX) Stock We Don't?
09:51am, Wednesday, 07'th Apr 2021
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
10:37am, Wednesday, 24'th Feb 2021
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
01:42pm, Monday, 22'nd Feb 2021
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics: A Name That Could Gain Traction In 2021
01:33pm, Monday, 08'th Feb 2021
We look at Heron Therapeutics for the first time since it received a CRL from the FDA late last Spring. The shares are up approximately one-third since we recommended to buy in that dip as the company
Heron Therapeutics (HRTX) Looks Good: Stock Adds 6.8% in Session
09:47am, Tuesday, 29'th Dec 2020
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy
10:00am, Wednesday, 11'th Nov 2020
This biotech titan should be a top player on the merger and acquisition scene next year.
